337 related articles for article (PubMed ID: 30810067)
1. Epidermal growth factor receptor paracrine upregulation in idiopathic pulmonary fibrosis fibroblasts is blocked by nintedanib.
Epstein Shochet G; Brook E; Eyal O; Edelstein E; Shitrit D
Am J Physiol Lung Cell Mol Physiol; 2019 Jun; 316(6):L1025-L1034. PubMed ID: 30810067
[TBL] [Abstract][Full Text] [Related]
2. TGF-β pathway activation by idiopathic pulmonary fibrosis (IPF) fibroblast derived soluble factors is mediated by IL-6 trans-signaling.
Epstein Shochet G; Brook E; Bardenstein-Wald B; Shitrit D
Respir Res; 2020 Feb; 21(1):56. PubMed ID: 32070329
[TBL] [Abstract][Full Text] [Related]
3. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis.
Hostettler KE; Zhong J; Papakonstantinou E; Karakiulakis G; Tamm M; Seidel P; Sun Q; Mandal J; Lardinois D; Lambers C; Roth M
Respir Res; 2014 Dec; 15(1):157. PubMed ID: 25496490
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
5. Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF).
Epstein Shochet G; Brook E; Israeli-Shani L; Edelstein E; Shitrit D
Respir Res; 2017 Jun; 18(1):122. PubMed ID: 28629363
[TBL] [Abstract][Full Text] [Related]
6. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
8. FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro.
Joannes A; Brayer S; Besnard V; Marchal-Sommé J; Jaillet M; Mordant P; Mal H; Borie R; Crestani B; Mailleux AA
Am J Physiol Lung Cell Mol Physiol; 2016 Apr; 310(7):L615-29. PubMed ID: 26773067
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia Inducible Factor 1A Supports a Pro-Fibrotic Phenotype Loop in Idiopathic Pulmonary Fibrosis.
Epstein Shochet G; Bardenstein-Wald B; McElroy M; Kukuy A; Surber M; Edelstein E; Pertzov B; Kramer MR; Shitrit D
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33805152
[TBL] [Abstract][Full Text] [Related]
10. Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis.
MacKenzie B; Korfei M; Henneke I; Sibinska Z; Tian X; Hezel S; Dilai S; Wasnick R; Schneider B; Wilhelm J; El Agha E; Klepetko W; Seeger W; Schermuly R; Günther A; Bellusci S
Respir Res; 2015 Jul; 16(1):83. PubMed ID: 26138239
[TBL] [Abstract][Full Text] [Related]
11. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
12. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Wollin L; Wex E; Pautsch A; Schnapp G; Hostettler KE; Stowasser S; Kolb M
Eur Respir J; 2015 May; 45(5):1434-45. PubMed ID: 25745043
[TBL] [Abstract][Full Text] [Related]
13. The Anti-fibrotic and Anti-inflammatory Potential of Bone Marrow-Derived Mesenchymal Stem Cells and Nintedanib in Bleomycin-Induced Lung Fibrosis in Rats.
Gad ES; Salama AAA; El-Shafie MF; Arafa HMM; Abdelsalam RM; Khattab M
Inflammation; 2020 Feb; 43(1):123-134. PubMed ID: 31646446
[TBL] [Abstract][Full Text] [Related]
14. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
15. Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.
Bourne MH; Kottom TJ; Hebrink DM; Choudhury M; Leof EB; Limper AH
Cells; 2021 Dec; 10(12):. PubMed ID: 34944010
[TBL] [Abstract][Full Text] [Related]
16. PI3K p110γ overexpression in idiopathic pulmonary fibrosis lung tissue and fibroblast cells: in vitro effects of its inhibition.
Conte E; Gili E; Fruciano M; Korfei M; Fagone E; Iemmolo M; Lo Furno D; Giuffrida R; Crimi N; Guenther A; Vancheri C
Lab Invest; 2013 May; 93(5):566-76. PubMed ID: 23439433
[TBL] [Abstract][Full Text] [Related]
17. Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of pulmonary fibrosis.
Herrmann FE; Wollin L; Wirth J; Gantner F; Lämmle B; Wex E
Br J Pharmacol; 2017 Nov; 174(21):3848-3864. PubMed ID: 28810065
[TBL] [Abstract][Full Text] [Related]
18. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
19. Novel Mechanisms for the Antifibrotic Action of Nintedanib.
Rangarajan S; Kurundkar A; Kurundkar D; Bernard K; Sanders YY; Ding Q; Antony VB; Zhang J; Zmijewski J; Thannickal VJ
Am J Respir Cell Mol Biol; 2016 Jan; 54(1):51-9. PubMed ID: 26072676
[TBL] [Abstract][Full Text] [Related]
20. Nintedanib: a novel therapeutic approach for idiopathic pulmonary fibrosis.
Dimitroulis IA
Respir Care; 2014 Sep; 59(9):1450-5. PubMed ID: 24782550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
